目標:探討NT-proBNP和cystatin c在慢性阻塞性肺疾�。–OPD）保留射血分數(shù)患者中的作用。探討NT-proBNP和cystatin c在慢性阻塞性肺疾�。–OPD）穩(wěn)定期和COPD急性加重期中的作用。探討NT-proBNP和cystatin對AECOPD和SCOD患者住院時間的影響。方法:本文對山東大學(xué)齊魯醫(yī)院收治的慢性阻塞性肺疾�。–OPD）患者進行回顧性研究。分析了2013年1月至2017年11月在齊魯醫(yī)院呼吸科診斷為慢性阻塞性肺�。–OPD）的患者的數(shù)據(jù)。COPD的定義是根據(jù)ICD 10標準/美國胸學(xué)會標準,支氣管擴張試驗后用力肺活量（FEV 1/FVC）小于70%的用力呼氣量/用力肺活量比值（FEV 1/FVC）。COPD分為兩大類:COPD急性加重期（AECOPD）和穩(wěn)定期COPD（SCOPD）。AECOPD根據(jù)GOLD指南定義為新出現(xiàn)或惡化的呼吸癥狀（喘息、呼吸困難、痰膿、發(fā)燒）,需要使用新藥,而將穩(wěn)定的COPD定義為已知的COPD患者,但沒有新的癥狀需要使用新的藥物�；�數(shù)據(jù)包括人口學(xué)資料、年齡、性別、體重和BMI。從醫(yī)院數(shù)據(jù)庫中提取血清標志物Cystat... 

【文章來源】：山東大學(xué)山東省 211工程院校 985工程院校 教育部直屬院校

【文章頁數(shù)】：103 頁

【學(xué)位級別】：碩士

【文章目錄】：
Acknowledgement
ENGLISH ABSTRACT
CHINESE ABSTRACT
ABBREVIATION
CHAPTER 1:INTRODUCTION
    1.1
    1.2 LITERATURE REVIEW
        1.2.1 EPIDEMIOLOGY
        1.2.2. PATHOGENESIS OF COPD IN RELATION TO INFLAMMATORY MARKERS
            1.2.2.1 Emphysema
            1.2.2.2. Chronic bronchitis
            1.2.2.3. Asthma coexist with COPD （ACOS）
        1.2.3. COPD AND CARDIOVASCULAR DISEASES INCLUDING LEFT HEART FAILURE
            1.2.3.1. inflammatory makers of COPD in relation to ischemic heart diseases
            1.2.3.2. Chronic obstructive pulmonary disease and Left and right heart failure
            1.2.3.3 Stroke secondary to inflammation from COPD
            1.2.3.4. Arrhythmias precipitated by inflammation from COPD
        1.2.4 CLINICAL FEATURES AND INVESTIGATIONS TEST FOR COPD
            1.2.4.1 Full blood picture
            1.2.4.2 BNP and NTproBNP in COPD patients with cardiovascular diseases
            1.2.4.3 Cystatin C and COPD patients with cardiovascular diseases
            1.2.4.4 Arterial blood gases
            1.2.4.5 Pulmonary function test
            1.2.4.6 Other tests
        1.2.5 Diagnosis of COPD
        1.2.6 COPD TREATMENT
            1.2.6.1 Non-pharmacologic therapies
            1.2.6.2 Medical treatment
        1.2.7 TREATMENT OF IN PATIENT WITH CARDIOVASCULAR DISEASES
CHAPTER 2: METHODOLOGY
CHAPTER 3: RESULTS
CHAPTER 4: DISCUSSION
CHAPTER 5: CONCLUSION
References
學(xué)位論文評閱及答辯情況表



本文編號：3152607